Navigation Links
Myocor Receives Approval for Percutaneous Trial
Date:12/5/2007

MAPLE GROVE, Minn., Dec. 5 /PRNewswire/ -- Myocor, Inc. announced that the U.S. Food and Drug Administration has granted conditional approval of the Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) feasibility study. The single-arm feasibility study will evaluate the safety and feasibility of the percutaneously implanted iCoapsys(TM) system in treating patients with mitral valve insufficiency caused by left ventricular dysfunction and coronary artery disease (CAD).

"Percutaneous valve repair is a new frontier of patient care," said Dr. Wes Pedersen, interventional director, complex valve disorders, at the Minneapolis Heart Institute. "The iCoapsys system offers patients an innovative, less invasive option for treating their functional mitral regurgitation (FMR). It is very exciting to be able to participate in the VIVID feasibility study as the principal investigator at Abbott Northwestern Hospital."

The iCoapsys device and implant procedure are based on the original, surgically implanted Coapsys(R) system. The first Coapsys device is currently being evaluated in the RESTOR-MV trial. Both devices are designed to reduce functional mitral regurgitation and reshape the left ventricle to provide a more complete reshaping therapy than traditional mitral valve repair. The development of the iCoapsys system will allow Myocor to provide physicians with both surgical and percutaneous options for their patients.

Initiation of the VIVID feasibility study is another significant milestone for Myocor, a privately held company. Since 1996, Myocor has developed a substantial portfolio of intellectual property related to mitral valve and left ventricle reshaping. "We have been very disciplined in bringing these devices through the design, manufacturing and trial processes with an eye on long-term success," said Myocor CEO, Jim Hickey. "We have been fortunate to have the experience of implanting over 120 Coapsys devices worldwide, the ded
'/>"/>

SOURCE Myocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... pipeline and new product development efforts. In the second ... Phase 2a study of AZ-002 (Staccato ® ... of patients with acute repetitive seizures.  Additionally, Alexza ... candidates for development - AZ-008 and AZ-009 - ...
(Date:7/31/2014)... 31, 2014  Decision Resources Group,s experts ... by the Affordable Care Act (ACA), which ... pharmaceutical therapies. The ACA altered how Managed ... regulations and expanded access via government-supported programs. ... exchanges—state-based marketplaces set up by states or ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Lazarus Effect Closes $5 Million Financing 2
(Date:7/31/2014)... (PRWEB) July 31, 2014 Developer Jamestown, ... on its Ponce City Market project in Atlanta’s ... Sears, Roebuck & Company building into best-in-class office, housing, ... OxBlue reviewed Jamestown’s experience with their construction webcam service ... , Jamestown wanted a construction camera for ...
(Date:7/31/2014)... Goshen, IN (PRWEB) July 31, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) rob people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
(Date:7/31/2014)... In many states and counties across the country, ... necessary life saving drugs. This requirement is for the safety ... high number of ambulances without proper security procedures. , In ... and even replaces the vital pain killers with saline. Later, ... the case in Baraboo, Wisconsin last November. According to court ...
(Date:7/31/2014)... Adventist Health System, which is ... Florida Hospital Tampa, Florida Hospital Carrollwood, Florida Hospital ... Pinellas, Florida Hospital Wesley Chapel, Florida Hospital Zephyrhills, ... Heartland Medical Center Lake Placid and Florida Hospital ... Most Wired Hospitals and Health Systems, which is ...
(Date:7/31/2014)... NV (PRWEB) July 31, 2014 Weblify has ... after 4 years of development and testing. The result ... monetized websites in as little as 5 minutes without knowing ... full Weblify review , Shane Michaels, an SEO expert, agrees ... quickly. “I’ve seen a lot of web site builders ...
Breaking Medicine News(10 mins):Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3
... 29 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... 13-D filing with the Securities and Exchange Commission from ... their intent to nominate a slate of five directors ... meeting. Amylin has not yet received the required notice ...
... DALLAS Jan. 29, 2009 Mice whose fat cells were ... "healthy" obesity when fed a high-fat diet, researchers at UT Southwestern ... but healthy mice lacked a protein called collagen VI, which normally ... a cage around a water balloon. The findings appear online and ...
... major public health problem. A new study examined the ... OA progression and symptoms. CS, unlike other chondroitin sulfate ... been approved as a prescription symptomatic slow acting drug ... published in the February issue of Arthritis & ...
... year,s worst city for asthmatics, experts say , , THURSDAY, Jan. ... "Asthma Capital of the United States," according to the Allergy ... most challenging places to live for people with the respiratory ... the top of this year,s list due to a number ...
... You Care" Contest Invites Participants to Share and ... CVS/pharmacy, the nation,s leading retail pharmacy, today announced ... Care" contest created to celebrate and honor caregivers ... caregivers and others to submit stories of caring ...
... , ... Irvine, CA (Vocus) January 29, 2008 -- ... improvement programs in a meaningful way, LifeMasters Supported SelfCare, Inc. has ... demonstration project targeting Medicare and Medicaid recipients in South Florida. , ...
Cached Medicine News:Health News:UT Southwestern researchers identify protein that may explain 'healthy' obesity 2Health News:Chondroitin slows progression and relieves symptoms of knee osteoarthritis 2Health News:St. Louis Ranked America's 'Asthma Capital' 2Health News:CVS/pharmacy Announces National Contest for Stories of Extraordinary Caregiving 2Health News:CVS/pharmacy Announces National Contest for Stories of Extraordinary Caregiving 3Health News:LifeMasters Offers Financial Incentives to Florida Physicians for Participation in Disease Management Programs 2Health News:LifeMasters Offers Financial Incentives to Florida Physicians for Participation in Disease Management Programs 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: